GAU 1633 \$

AMENDMENT TRANSMITTAL LETTER

DOCKET NUMBER: P-LJ 3650

MAY 1 2 2000

SARIAL NO: 09/388,221

FILING DATE: September 1, 1999 EXAMINER: D. Nikodem

GROUP ART UNIT: 1633

NVENTION.

NOVEL CARD PROTEINS INVOLVED IN CELL DEATH REGULATION

TO COMMISSIONER FOR PATENTS

RECEIVED

MAY 19 2000

TECH CENTER 1600/2900

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C., 20231 on May 9, 2000

By: Robert T. Ramos Reg. No.: 37,915

May 9, 2000 Date of Signature

Transmitted herewith is a response in the above-identified application.

- X Small Entity status of this application has been established under 37 CFR 1.27 by a verified statement previously submitted.
- X Paper copy of Sequence Listing pp 1-71 with diskette.
- X Copy of Notice to Comply with Requirements for Patent Applications containing nucleotide and/or amino acid sequence disclosures.
- X Statement under 37 C.F.R. § 1.821(f) and (g).
- X Petition for Extension of Time is enclosed.
- X No additional claims fee is required.
- \_\_\_\_ An additional claims fee is required and has been calculated as shown below:

## CLAIMS AS AMENDED

	NUMBER AFTER AMEND- MENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		NUMBER OF EXTRA CLAIMS PRESENTED		RATE		FEE		
							SMALL ENTITY	OTHER ENTITY		SMALL ENTITY	OTHER ENTITY
TOTAL CLAIMS	65	1	65	_	0	×	\$9	\$18	_	\$0.00	\$0.00
INDEPEN- DENT CLAIMS	14	-	14	-	0	х	\$39	\$78	-	\$0.00	\$0.00
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM			YES		X NO		\$130	\$260	=	\$0.00	\$0.00
							TOTAL ADDITION	NAL FEE		\$0.00	\$0.00

- \* If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, write "20" in this space.
- \*\* If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.

RECEIVED

HM 22 7000

TECHCENTER 1600/2000

Inventors: John C. Reed 09/388,221 Serial No.: Filed: September 1, 1999

Page 2

If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 0, write "0" in the space.

- Please charge my Deposit Account No. 03-0370 the amount of \$\_\_\_\_\_. A duplicate copy of this sheet is enclosed.
- A check in the amount of \$55.00 is enclosed which covers the fee for a one-month extension of time.
- The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 03-0370. A duplicate copy of this sheet is enclosed.
  - X Any additional filing fees required under 37 C.F.R. 1.16.
  - Any patent application processing fees under 37 C.F.R. \_X\_ 1.17.
- The Commissioner is hereby authorized to charge to Deposit Account No. 03-0370 any fees under 37 CFR 1.17 which may be required under 37 CFR 1.136(a)(3) for an extension of time in any concurrent or future reply requiring a petition for extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Robert T. Ramos

Registration No.: 37,915 CAMPBELL & FLORES LLP

4370 La Jolla Village Drive

7<sup>th</sup> Floor

San Diego, California 92122

858-535-9001

USPTO CUSTOMER NO. 23601

## SEQUENCE LISTING WITH DISKETTE P-LJ 3650 Serial No.:09/388,221

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on May 9, 2000.

Βv

Robert T. Ramos, Reg. No.: 37,915

May 9, 2000

Date of Signature

Application No.: 09/388,221

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

O The nucle comply wi MAY 1following	eotide and/or amino acid sequence disclosure contained in this application does not ith the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the reason(s):
PADEMARY	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
$\boxtimes$	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other:
Ар	plicant Must Provide:
X	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
$\boxtimes$	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For	questions regarding compliance to these requirements, please contact:
For	Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212 entIn Software Program Support (SIRA) Technical Assistance
	To Purchase Patentin Software 703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE